IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RESPONSE UNDER RUL EXPEDITED HANDLING PROCEDURES

In re Patent Application of Examiner: Zeman

Atty Dkt. 2551-105

1631

Date: May 17, 2005

C# M#

Maertens et al

Serial No. 08/836,075

Filed: April 21, 1997

Title:

NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS

PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENTS

Corres, and Mail

Mail Stop AF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT & CITED REFERENCE

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other

signature thereon.		•	
☐ Correspondence Address Indication	n Form Attached.		
Fees are attached as calculated below: Total effective claims after amendment 0 previously paid for 20 (at least 20) =	minus highest number 0 x \$50.00	\$0.00 (1202)/\$0.00 (2202)	\$
Independent claims after amendment previously paid for 3 (at least 3) =	minus highest number 0 x \$200.00	\$0.00 (1201)/\$0.00 (2201)	\$
If proper multiple dependent claims now added for Petition is hereby made to extend the current due paper and attachment(s)	date so as to cover the fili One Month Extension \$ Two Month Extensions \$4 Three Month Extensions \$1	\$360.00 (1051)/\$180.00 (2051)	
Termiàal disclaimer enclosed, add		\$130.00 (1814)/ \$65.00 (2814)	\$
☐ Applicant claims "small entity" status. ☐ S	Statement filed herewith		
Rule 56 Information Disclosure Statement Filing R	-ee	\$180.00 (1806)	\$ 180.00
Assignment Recording Fee		\$40.00 (8021)	\$
Other:			\$
		TOTAL FEE ENCLOSED	\$ 180.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this

firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor Arlington, Virginia 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 BJS:

05/18/2005 SZEWDIE1 00000005 08836075

01 FC:1806

180.00 OP

By Atty: B. J. Sadoff, Reg. No. 36,663

NIXON & VANDERHYE P.C.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Maertens et al

Atty. Ref.:

2551-105

Serial No.

08/836,075

Group:

1631

Filed:

April 21, 1997

Examiner:

Zeman

For:

NEW SEQUENCES OF HEPATITIS C VIRUS

GENOTYPES AND THEIR USE AS PROPHYLACTIC,

THERAPEUTIC AND DIAGNOSTIC AGENTS

Mail Stop AF

Commissioner for Patents

May 17, 2005

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C
2.(a)	Statement Pursuant to 37 CFR 1.97(c)

- [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C
- 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c)
 [before Final Office Action or Allowance (requires Rule 97(e)
 Statement or Rule 17(p) fee)] \$180.00
- Statement and Rule 17(p) fee), but before final fee payment]
 \$1.00
 Pursuant to 37 CFR 1.97(d)
 [after Final Office Action or Allowance (requires Rule 97(e)
 Statement and Rule 17(p) fee), but before final fee payment]
 \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each

05/18/2005 SZEWDIE1 00000005 08836075

01 FC:1806

180.00 OP

This paper is submitted in accordance with:

identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

-	-					
	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]				
	6.	37 (and	CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];			
		a)	The required Statement made in item 8 below; or			
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.			
\boxtimes	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and				
	\boxtimes	a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith as attached Credit Card Payment Form; and			
	\boxtimes	b)	The required Statement is stated in item 8 below.			
\boxtimes	8.	Statement under 37 CFR 1.97(e)				
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from the Japanese Patent Office in a counterpart foreign application on April 12, 2005, i.e., not more than three months prior to the filling of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filling of this IDS); or			
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
\boxtimes	9.	Info	ase charge all deficiency fees associated with the submission of this rmation Disclosure Statement and any other fees applicable to this lication to Deposit Account No. 14-1140. An original and one (1) copy of			

Maertens et al Serial No. 08/836,075

this document are enclosed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

J. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

Sheet 1 ATTY, DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE CITATION 08/836,075 **APPLICANT** Maertens et al (Use several sheets if necessary) **FILING DATE** GROUP 1631 April 21, 1997 U.S. PATENT DOCUMENTS *EXAMINER FILING DATE IF APPROPRIATE NAME CLASS **SUBCLASS** INITIAL DOCUMENT NUMBER DATE FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Apichartpiyakul et al., Journal of Clinical Microbiology, September 1994, pp 2276-2279, vol. 32, No. 9

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

*Examiner

Form PTO-FB-A820 (Also PTO-1449)